HIT

Serial Number 78420082
601

Registration Progress

Application Filed
May 17, 2004
Under Examination
Approved for Publication
Published for Opposition
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: HIT
Previous Owner: Jagotec AG
Classes: 005

Trademark Image

HIT

Basic Information

Serial Number
78420082
Filing Date
May 17, 2004
Abandonment Date
July 5, 2005
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
601
Status Date
Jul 7, 2005
Classes
005

Rights Holder

Jagotec AG

03
Address
Eptingerstrasse 51
Muttenz 4132
CH

Ownership History

Jagotec AG

Original Applicant
03
Muttenz CH

Legal Representation

Attorney
John J. O'Malley

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

7 events
Date Code Type Description Documents
Jul 8, 2005 MAB1 O ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT Loading...
Jul 7, 2005 ABN1 O ABANDONMENT - EXPRESS MAILED Loading...
Jul 5, 2005 EXAR I TEAS EXPRESS ABANDONMENT RECEIVED Loading...
Jan 3, 2005 CNRT F NON-FINAL ACTION MAILED Loading...
Jan 3, 2005 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 15, 2004 DOCK D ASSIGNED TO EXAMINER Loading...
May 24, 2004 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations adapted for the topical, injectable, and intravenous treatment of the following, cancer, increasing activity of macrophages; reduction of swelling in the brain of person suffering brain trauma; herpes, canker sores, shingles; renal failure, cardiac insufficiency, hypertension, oedema; infection, acne, mononucleosis; transplants; inflammation, elimination of tumor breakdown material (toxins and debris), decreasing side effects, relief of pain; detoxification, brochodilation; vascular ischemia; HIV(AIDS); diabetes; post-menopause; prevention of topical infection; reduction of swelling; hypertension, cardiac insufficiency; prostaglandin synthesis inhibition; enhancement of oxygenation of tissue by perfusion fluid bathing of the tissue (for transplantation purposes); sub-retinal neovascularization and as an adjunct to the treatment of cancer to prevent metastasis; arthritis or pannus; cancer tumors; inhibiting angiogenesis; controlling angiogenesis; regressing angiogenesis; basal cell carcinoma; actinic keratoses; liver spots; squamous cell tumors; metastatic cancer of the breast to the skin; primary and metastatic melanoma of the skin; malignancies and/or tumor of the skin; genital warts (condyloma acuminata); cervical cancer; human papilloma virus (HVP); psoriasis, corns on the feet; and hair loss on the heads of pregnant women; topical treatment of pain in the skin and or exposed tissue; clearing of atherosclerosis; prevention of arterial restenosis after balloon angioplasty; macrophage infiltration; pharmaceutical preparations comprising hyaluronan; licensing of intellectual property technology and research and developing for others, regarding pharmaceutical preparations, including pharmaceutical preparations comprising hyaluronan, adapted for the topical, injectable, and intravenous treatment of medical conditions and disease in humans
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005